Automate Your Wheel Strategy on LGVN
With Tiblio's Option Bot, you can configure your own wheel strategy including LGVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LGVN
- Rev/Share 0.1381
- Book/Share 0.843
- PB 0.949
- Debt/Equity 0.0505
- CurrentRatio 3.4315
- ROIC -1.3232
- MktCap 16636960.0
- FreeCF/Share -0.9506
- PFCF -1.1658
- PE -0.6478
- Debt/Assets 0.0382
- DivYield 0
- ROE -0.959
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LGVN | ROTH MKM | -- | Buy | -- | $10 | Dec. 6, 2024 |
News
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City.
Read More
Longeveron Announces Up To $17.5 Million Public Offering
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 14,705,885 shares of Class A common stock at a combined public offering price of $0.85 per share of Class A common stock (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have …
Read More
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m.
Read More
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Longeveron has licensed issued US Patent 12,168,028 B2 , entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs) New technology substantially advances Longeveron's repertoire of stem cell therapy technologies Opportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that it has licensed an issued US patent (12,168,028 B2) for …
Read More
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.
Read More
Longeveron® Appoints Than Powell as Chief Business Officer
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program.
Read More
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.
Read More
Longeveron® to Attend BIO International Convention 2025
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
Read More
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. “We're proud to be a Semifinalist team …
Read More
Longeveron® to Present at the 37th Annual Roth Conference
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company's fireside chat: Date: Tuesday, March 18, 2025 Time: 9:00 – 9:25 a.m.
Read More
About Longeveron Inc. (LGVN)
- IPO Date 2021-02-12
- Website https://www.longeveron.com
- Industry Biotechnology
- CEO Mohamed Wa'el Ahmed Hashad
- Employees 25